Search research articles
Contact Us
Filters
Showing results (171-180 of 272) with videos related to
Page
of 28
Sort By:
Kidney International
|
October 21, 2022
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt, Richard Lafayette, Jens Kristensen, et al.
Journal of the American Society of Nephrology : JASN
|
April 17, 2025
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
BMC Nephrology
|
May 10, 2022
Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study
Cédric Jäger, Susanne Stampf, Karen Molyneux, et al.
The Biochemical Journal
|
August 14, 2015
The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease
Gar Kay Hui, David W Wright, Owen L Vennard, et al.
Lancet (London, England)
|
August 17, 2023
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Richard Lafayette, Jens Kristensen, Andrew Stone, et al.
Kidney International Reports
|
April 14, 2025
Systematic Scoping Review of Socioeconomic Burden and Associated Psychosocial Impact in Patients With Rare Kidney Diseases and Their Caregivers
Anna Palagyi, Agnivo Sengupta, Monica Moorthy, et al.
Kidney International Reports
|
January 16, 2026
Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease?
Mahtab Mashayekhi, Jonathan Barratt, Areefa Alladin, et al.
Kidney International Reports
|
May 14, 2023
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Dana V Rizk, Brad H Rovin, Hong Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 19, 2022
Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis
Sarah Mayer-Hain, Kathleen Gebhardt, Matthias Neufeld, et al.
Kidney International Reports
|
January 16, 2026
Iptacopan in Patients With IgA Nephropathy From East Asia
Hong Zhang, Vlado Perkovic, Jonathan Barratt, et al.
Page
of 28
Search research articles
Search
Showing results (171-180 of 272) with videos related to
Sort By:
Page
of 28
Kidney International
|
October 21, 2022
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt, Richard Lafayette, Jens Kristensen, et al.
Journal of the American Society of Nephrology : JASN
|
April 17, 2025
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
BMC Nephrology
|
May 10, 2022
Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study
Cédric Jäger, Susanne Stampf, Karen Molyneux, et al.
The Biochemical Journal
|
August 14, 2015
The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease
Gar Kay Hui, David W Wright, Owen L Vennard, et al.
Lancet (London, England)
|
August 17, 2023
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Richard Lafayette, Jens Kristensen, Andrew Stone, et al.
Kidney International Reports
|
April 14, 2025
Systematic Scoping Review of Socioeconomic Burden and Associated Psychosocial Impact in Patients With Rare Kidney Diseases and Their Caregivers
Anna Palagyi, Agnivo Sengupta, Monica Moorthy, et al.
Kidney International Reports
|
January 16, 2026
Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease?
Mahtab Mashayekhi, Jonathan Barratt, Areefa Alladin, et al.
Kidney International Reports
|
May 14, 2023
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Dana V Rizk, Brad H Rovin, Hong Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 19, 2022
Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis
Sarah Mayer-Hain, Kathleen Gebhardt, Matthias Neufeld, et al.
Kidney International Reports
|
January 16, 2026
Iptacopan in Patients With IgA Nephropathy From East Asia
Hong Zhang, Vlado Perkovic, Jonathan Barratt, et al.
Page
of 28